ACVRL1 and Alzheimer disease: We show that ALK1 immunoreactivity in hippocampalarteriolar walls is reduced in AD patients, as compared with subjects with early ADpathologic changes that are either cognitively intact or with minimal cognitive impairment,irrespective of amyloid accumulation measured by the intensity of Aβ vascularimmunohistochemistry (IHC) signal.